Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

AramcholPositive

AI Analysis

Summary

Galmed announced development of a novel brain-penetrating formulation of its SCD1 inhibitor Aramchol in collaboration with Barcode Nanotech, designed to overcome the blood-brain barrier challenge that affects 98% of drugs.

Importance:5/10

Sentiment:

0.60

drug formulationCNSblood-brain barrierSCD1 inhibitorpartnership

Related Companies

$DMII

Read the original article

Published by PR Newswire Biotech on April 9, 2026 11:30 AM

Read Original